Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw strong trading volume on Wednesday . 647,346 shares traded hands during mid-day trading, a decline of 81% from the previous session’s volume of 3,457,649 shares.The stock last traded at $15.12 and had previously closed at $15.16.
A number of equities analysts have recently issued reports on the company. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Leerink Swann upped their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, January 15th. Finally, Cowen reiterated a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $19.06.
The company has a market cap of $2,450.00, a price-to-earnings ratio of -17.55 and a beta of 1.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.11). Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. The business had revenue of $14.73 million during the quarter, compared to analysts’ expectations of $14.50 million. equities research analysts anticipate that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.
In other news, major shareholder Perceptive Advisors Llc bought 335,827 shares of the firm’s stock in a transaction dated Monday, March 5th. The stock was purchased at an average price of $13.56 per share, with a total value of $4,553,814.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John F. Crowley sold 18,970 shares of the stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $14.75, for a total value of $279,807.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 207,870 shares of company stock valued at $3,066,112. Company insiders own 3.40% of the company’s stock.
Large investors have recently made changes to their positions in the company. Sage Capital Advisors llc bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $154,000. Engineers Gate Manager LP bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $155,000. Neuberger Berman Group LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $196,000. Great West Life Assurance Co. Can raised its position in shares of Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 4,145 shares in the last quarter. Finally, Sterling Capital Management LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $218,000.
ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics (FOLD) Sees Large Volume Increase” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/16/amicus-therapeutics-fold-sees-large-volume-increase.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.